The University of California at Los Angeles is presented as an important institutional connection in the mid-century Los Angeles LSD research scene, rather than as the setting of one formally bounded project. Sidney Cohen worked first at Brentwood VA and later at the university; Betty Eisner had recently completed her doctorate there; and Cohen, Eisner, and Oscar Janiger became leading figures in a research hub loosely centered on the institution. Their work helped challenge the idea that LSD simply reproduced psychosis and gave the Los Angeles group a distinctive place in the emerging history of psychedelic therapy.

Institutional Anchor and Research Network

The book locates the university within a cooperative, geographically dispersed research culture. By the mid-1950s, perhaps a dozen LSD research hubs existed across North America and Europe. Rather than functioning as isolated competitors, many kept in close contact, sharing techniques, findings, and sometimes supplies of the drug. In this account, the Los Angeles group around Cohen, Eisner, and Janiger was one node in that wider network, with UCLA an important professional and institutional point of reference.

The wording matters: the research hub was loosely centered on the university, not described as a single university department or as a program operating entirely on its campus. Cohen’s career connected the scene to clinical medicine: he was an internist at Brentwood VA and later UCLA, and his earlier research interests included chemically induced psychoses. Eisner brought a recently completed UCLA doctorate and a psychologist’s training. Janiger, a psychiatrist, was another central figure in the group. Their different professional positions helped make Los Angeles a meeting point for research, clinical practice, and public accounts of LSD experience.

From Psychosis to a Different Interpretation

Cohen initially approached LSD through the psychotomimetic model: the expectation that the drug would temporarily reproduce mental illness. His own experience in October 1955 unsettled that interpretation. Instead of feeling trapped in madness, he encountered a state of profound tranquillity that he did not consider a temporary psychosis. Eisner later described his developing term for this state as unsanity, a condition beyond the ego’s control. The experience did not, by itself, settle the scientific question, but it sharpened the tension between the model the researchers had inherited and the reports they were hearing from volunteers.

That tension was part of a broader reconsideration already under way among LSD researchers. At Weyburn, Humphry Osmond and Abram Hoffer were questioning whether some experiences they had understood through delirium tremens and psychosis might be better interpreted as spiritual or visionary events. The Los Angeles researchers’ own observations contributed to the same shift: many volunteers reported difficult or frightening sessions, but relatively few displayed the full psychosis predicted by the original model. UCLA’s significance in this history therefore lies partly in its connection to a research community revising its basic vocabulary for what LSD did.

Therapy, Patients, and Creative Work

Cohen, Eisner, and Janiger incorporated LSD into recurring therapeutic sessions, increasing doses from week to week. Their principal patients were people with neuroses, alcoholism, or relatively minor personality disorders: patients who were generally functional, articulate, and motivated to improve. The aim was to bring them into contact with subconscious material, including repressed emotions and buried memories of childhood trauma. The treatment was not presented simply as an isolated drug effect; it unfolded through a continuing therapeutic relationship and a sequence of sessions.

The group also extended its interest beyond people seeking treatment. Hundreds of painters, composers, and writers received LSD in the belief that access to the subconscious might expand creative capacity. The same therapeutic setting could thus be understood as a route into painful personal material or as an instrument for artistic exploration. This breadth gave the Los Angeles network a public profile beyond conventional psychiatric care, but it also meant that the claims attached to the drug covered markedly different aims and kinds of participants.

Early results appeared encouraging. Cohen and Eisner reported marked improvement in sixteen of their first twenty-two patients. A later review of psycholytic therapy papers published from 1953 through 1965 estimated success rates of 70 percent for anxiety neurosis, 62 percent for depression, and 42 percent for obsessive-compulsive disorder. Those figures made a persuasive case to supporters, but few attempts had been made to reproduce the results in controlled trials. The evidence therefore described a promising clinical practice, not a definitive demonstration that LSD caused the reported improvements.

Public Profile and Limits of the Evidence

By the end of the 1950s, psycholytic LSD therapy had become routine in affluent Los Angeles circles, including Beverly Hills. Some therapists charged more than five hundred dollars for a session while often receiving LSD free from Sandoz. The treatment also attracted favorable press: accounts of frightening experiences gave way to testimonials from celebrities who described transformation. Cary Grant, who had more than sixty sessions, publicly praised the therapy in 1959 and said he felt born again. Such attention brought the Los Angeles practice into popular view, but celebrity testimony was not a substitute for controlled clinical evidence.

The contrast with the Canadian replication effort makes that limitation especially clear. The Addiction Research Foundation in Toronto set out to test the Saskatchewan alcohol-treatment results under tighter controls. Participants were placed in neutral rooms, received little engagement from clinicians, and were asked to complete extensive questionnaires; some were constrained or blindfolded. The outcomes did not match those reported by Osmond and Hoffer, and several volunteers had terrifying experiences. Critics took the results as evidence that the treatment was less effective under rigorous conditions; supporters argued that the stripped-down environment had removed conditions essential to successful therapy. The comparison did not directly test the Los Angeles group’s full range of practices, but it exposed a central methodological problem for psychedelic research: drug effects could not easily be separated from the human and environmental conditions of a session.

The university’s place in the narrative is consequently both concrete and qualified. It connects Cohen and Eisner to the Los Angeles network that developed recurring LSD psychotherapy and brought the practice to patients, artists, and the wider public. At the same time, the evidence does not establish a single UCLA-based treatment program or resolve whether the reported benefits would withstand stronger replication. The institution marks a point where clinical research, evolving interpretations of psychedelic experience, and a highly visible therapeutic culture converged—while leaving the question of how much each contributed to the outcomes unsettled.